Blog
Drug Target Encyclopedia Series (2) — BCMA
Release Time：
2025-12-03 14:52
B-cell maturation antigen (BCMA) is a key member of the tumor necrosis factor receptor superfamily (TNFRSF17), primarily expressed on mature B cells and plasma cells. Its critical role in B-cell survival and differentiation makes it an essential target for treating multiple myeloma (MM) and other B-cell disorders. Unlike other B-cell markers, BCMA is absent on naïve and memory B cells, as well as hematopoietic stem cells, allowing for selective depletion of malignant plasma cells while preserving normal B-cell populations.
BCMA-targeted therapies have revolutionized multiple myeloma treatment, leading to the development of antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), and chimeric antigen receptor (CAR) T-cell therapies.
FDA-approved BCMA therapies include:
Belantamab mafodotin (Blenrep) – An ADC that delivers a cytotoxic payload to BCMA-expressing cells.
Teclistamab (Tecvayli) – A bispecific antibody that engages both BCMA and CD3 to recruit T cells for targeted killing.
Idecabtagene vicleucel (Abecma) & Ciltacabtagene autoleucel (Carvykti) – CAR-T therapies that harness the power of engineered T cells to eradicate myeloma cells.
Beyond multiple myeloma, BCMA-based therapies are being explored in systemic lupus erythematosus (SLE) and other autoimmune conditions, aiming to restore immune balance by selectively targeting pathogenic plasma cells.
The next generation of BCMA-targeted treatments focuses on overcoming resistance, enhancing durability, and reducing toxicity, ensuring better clinical outcomes for patients.
Need BCMA for drug discovery?
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898